A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands
Authors:
Open Access
- 2 May 2018
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 37 (8) , 2291-2296
Abstract
Urate-lowering therapy (ULT) is a recommended life-long treatment for gout patients. However, despite these recommendations, recurrent gout attacks are commonly observed in clinical practice. The purpose of this study was to assess the levels of compliance and persistence to ULT in The Netherlands, in order to reflect on the current gout care delivered by health professionals. Anonymous prescription records were obtained from IQVIA’s Dutch retrospective longitudinal prescription database, containing ULT dispensing data for allopurinol, febuxostat, and benzbromarone from November 2013 to July 2017. Compliance to ULT was determined by calculating the proportion of days covered (PDC) over 12 months. Persistence over 12 months was evaluated by determining the time to discontinuation, without surpassing a refill gap of > 30 days. Association of PDC and persistence with age, gender, and first prescriber were examined using beta regression- and cox-regression models, respectively. There were 45,654 patients who met the inclusion criteria. Overall, 51.7% of the patients had a ULT coverage of ≥ 80% of the days in 1 year (PDC ≥ 0.80), and 42.7% of the patients were still persistent after 1 year. Men, older patients, and patients whose first prescriber was a rheumatologist were more persistent and had a higher PDC. Our results show that medication adherence to ULT after 1 year is suboptimal, considering that current guidelines recommend ULT as a life-long treatment. Future studies addressing the reasons for treatment cessation and improving treatment adherence seem warranted.Keywords
Funding Information
- Grünenthal B.V.
This publication has 20 references indexed in Scilit:
- 2016 updated EULAR evidence-based recommendations for the management of goutAnnals of the Rheumatic Diseases, 2017
- Rising burden of gout in the UK but continuing suboptimal management: a nationwide population studyAnnals of the Rheumatic Diseases, 2015
- Overcoming adherence issues and other barriers to optimal care in goutCurrent Opinion in Rheumatology, 2015
- Gout: why is this curable disease so seldom cured?Annals of the Rheumatic Diseases, 2012
- 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaArthritis Care & Research, 2012
- Patient and provider barriers to effective management of gout in general practice: a qualitative studyAnnals of the Rheumatic Diseases, 2012
- Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008Arthritis & Rheumatism, 2011
- Revisiting the pathogenesis of podagra: why does gout target the foot?Journal of Foot and Ankle Research, 2011
- Quality of Life and Disability in Patients with Treatment-Failure GoutThe Journal of Rheumatology, 2009
- A Checklist for Medication Compliance and Persistence Studies Using Retrospective DatabasesValue in Health, 2007